FDA
approval
· 2017-12-19
FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
Summary
FDA approved a supplemental application to introduce an extended-release formulation of Pristiq (desvenlafaxine succinate) from Wyeth Pharmaceuticals, a Pfizer …
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for PRISTIQ EXTENDED-RELEASE (DESVENLAFAXINE SUCCINATE)